Despite advancements in the treatment of acute lymphoblastic leukemia (ALL), survival rates vary greatly based on factors such as cancer subtype and geographical location. The use of diagnostic tools like immunophenotyping and measurable residual disease (MRD)... ...

请注册登录后继续浏览